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ABSTRACT 
 
Change management is now considered a core managerial competency.  Under the fiscal and 
regulatory environment that currently applies, healthcare managers and professionals must be 
competent in initiating, guiding and managing change to drive efficient and effective delivery 
of care.  
This dissertation describes a successful journey through a planned change effort. An 
evidence-based approach to monitoring adverse effects of clozapine was implemented in a 
Community (Adult) Mental health Team. Clozapine has the sole license for treatment-
resistant schizophrenia, but has been associated with several potentially life-threatening 
adverse effects.  Accumulating evidence suggests that not enough attention is paid to 
recognising and addressing these adverse effects, a finding replicated in an internal audit of 
practice within this service. Additional external regulatory imperatives provided further 
impetus for change. 
The change was implemented using the HSE change model as a guiding tool. A range of 
qualitative and quantitative tools that were used to evaluate the change revealed successful 
attainment of set objectives, and also identified early signs for long term sustenance and 
continuous quality improvements. 
On reflection, the challenges encountered during this project have had considerable formative 
impact on the learning and practice of the author. It is hoped that future service evaluations 
will confirm attainment of its intended long term impact, while also providing objective bases 
for further continuous quality improvement initiatives. 
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1. CHAPTER 1: INTRODUCTION  
 
1.1. Introduction  
Change is a constant feature of life. It has assumed a particular strategic significance 
in the continuously evolving health and social care environment of modern times. In 
this dissertation, the author describes the assessment, planning, implementation and 
evaluation of an initiative aimed at improving the routine monitoring and 
management of physical health consequences of clozapine, a medication used for the 
treatment of schizophrenia. This first chapter introduces the concept of organisational 
change. A discussion follows on the change project, the rationale for the project, the 
aims and objectives and the organisational context in which the change was 
implemented. The expected organisational impact is outlined and the chapter 
concludes by setting out the broad layout for the remainder of this dissertation. 
 
1.2. Background  
Recent decades have witnessed tremendous advances in the scope and quality of care 
across all medical and allied health disciplines. Perhaps the most exponential of these 
advances have occurred in the field of mental health with the seismic transition from 
institutionalisation to community-based care (Wright, 1997). Other significant 
advances include unprecedented reforms in mental health legislations (Kelly, 2008); 
novel insights into brain neuroplasticity (Pascual-Leone et al, 2005) and the 
consequent advent of safer and more effective investigative and therapeutic agents. 
These reforms have resulted in safer practice and improved quality of care. They have 
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been underpinned by change, made by people within organisations. 
From a clinical standpoint, one of the significant advances in contemporary 
psychiatric practice has been the greater attention paid to the interface between 
psychiatry and medical disorders (Mangtani et al, 2005; Whyte et al, 2007; Roberts et 
al, 2007). It is now widely recognised that people with major mental illnesses have a 
greater propensity to suffer with medical disorders, and that they tend to have worse 
outcomes from treatment (Mitchell, 2012; Connolly & Kelly, 2005). Their psychiatric 
illness, its treatment and the lifestyle choices they make have all been found to 
contribute to this excess morbidity and mortality (Malhi et al, 2010; Connolly & 
Kelly, 2005). 
  
Psychiatry has long been renowned for its holistic approach to care planning and 
delivery (Angyal, 1948). Within this context, psychiatrists must take adequate care to 
recognise, prevent and address adverse effects associated with the therapeutic 
interventions that they implement (UEMS, 2009). They must also remain vigilant to 
medical conditions that may be incidental, contributory or consequential to mental 
illness and its treatment. Also, because co-morbidity is commonplace in psychiatry, 
the psychiatrist has a duty to actively collaborate with other specialists at various 
interfaces, including at primary and secondary care levels to minimise overall illness 
burden and enhance recovery (UEMS, 2009). 
There is growing concern that current practices deviate considerably from the tenets 
espoused above, particularly in regard to the physical health care of psychiatric 
patients (Mitchell et al, 2012). Evidence now abounds on the association between 
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clozapine, the only medication licensed for treatment resistant schizophrenia, and 
several adverse physical health consequences (Malhi et al, 2010; Mortimer, 2011; 
Bolton, 2011). Several authors have commented on widespread shortfalls in care 
provision for patients on clozapine treatment (Bolton, 2011, Mitchell et al, 2012; 
Kohen, 2005). It was therefore considered prudent to examine how this mental health 
service compared with international standards and practices in this area. 
 
1.3. Organisational Context 
This project was carried out within a Community Mental Health Service (CMHS) that 
provides specialist assessment and treatment for adults of working age who suffer 
with major mental illness. The service is state-funded, providing outpatient and day 
services for a predominantly rural population catchment area of 35,000. Referrals are 
almost exclusively from local General Practitioners (GPs) who are self-employed 
contractors to the health service.  
 
The main hub of the service is a community-based acute day hospital from where a 
multi-disciplinary team (MDT) of mental health professionals operate. The MDT 
comprises one Consultant Psychiatrist (the author), one Psychiatric Registrar, six 
Clinical Nurse Specialists, 2 Community Mental Health Nurses, and one each of 
Clinical Psychologist, Mental Health Social Worker, Occupational Therapist, 
Addiction Counsellor and Family Therapist. The team is supported by 3 
administrative and secretarial staff. A subset of the team comprising 5 members from 
different disciplines (including the author) constitutes the Sector Management Team. 
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Team leadership is provided by the Consultant Psychiatrist (author) who is also a 
member of the Senior Management Team of the County Mental Health Service. 
Cases referred to the team fall within the broad range of common psychiatric illnesses 
that typically present to an adult mental health service. These include psychotic 
disorders, mood disorders, anxiety disorders, alcohol and substance misuse as well as 
personality disorders. In line with best practice, the burden of ongoing clinical 
responsibility is shared with patients’ GPs, including during the acute phase of their 
treatment, with regular updates on clinical progress and changes in treatment regimen. 
Insofar as is possible and appropriate, efforts are made to involve families and carers 
in the planning and delivery of care. 
 
Patients on Clozapine were seen regularly in a dedicated Nurse-led clozapine clinic 
for regular full blood count monitoring as stipulated by the product license. Under 
strict governance protocol for the clinical use of clozapine, patients attend weekly for 
the first 18weeks, then fortnightly for up to one year and monthly thereafter. The 
focus of this clinic was the detection and management of agranulocytosis, a rare but 
potentially fatal adverse effect of clozapine. Monitoring was carried out by two 
nursing staff that had received specialist training for the purpose. The team 
coordinator - an Assistant Director of Nursing (ADON) and the Clinical Nurse 
Manager for the Day Hospital provided nursing supervision. Patients were also 
assessed for blood pressure, pulse, glucose, lipids, liver function and weight. 
However, these other assessments were ad hoc as there were no guidelines and 
protocols in place for the monitoring of these parameters; nor were there standards or 
procedures for follow-up in the event that abnormalities were detected.   
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1.4. The Change Project 
The change involved the development and introduction of a structured and systematic 
approach to monitoring and managing the adverse effects of clozapine. Clozapine is 
the only antipsychotic medication licensed for treatment-resistant schizophrenia.  
Unfortunately, it has a number of problematic and sometimes life threatening adverse 
effects that necessitate long term monitoring (Metzer, 2010; Mortimer, 2011). The 
most notorious of these, agranulocytosis, already has a robust and effective 
monitoring service currently provided by the drug manufacturer in line with the 
product license (Norvatis, 2010).  
 
The scope of this change initiative therefore was to introduce a structured mechanism 
for monitoring and managing those various other adverse effects that contribute to the 
excess morbidity and mortality associated with the use of clozapine. This involved 
developing and implementing a local practice guideline on clozapine monitoring, 
enhancing the knowledge and attitude of staff to the safe clinical use of clozapine and 
facilitating active participation of patients in their own physical healthcare through 
improved awareness of modifiable risk factors. The change also involved the 
development of a structured proforma for documenting relevant clinical parameters; 
and a standardised letter for communicating any identified abnormalities to GPs with 
a view to ensuring prompt and effective interventions when necessary. There was also 
the introduction of medical back-up to the previously nurse-led clozapine clinic.  
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1.5. Rationale for selecting the change 
The 2010 guidelines on schizophrenia from the National Institute for Health and 
Clinical Excellence (NICE) acknowledged the wide range of adverse effects 
associated with clozapine, and stipulated evidence-based guidelines for the physical 
health care of these patients (NICE, 2010). It was against this gold standard that the 
author previously compared the current practice of this mental health service as part 
of an audit cycle. The main finding of this continuous quality improvement initiative 
was a breach of international best practice in this area of clinical care. In addition, the 
whole area of care planning and delivery also come into focus following an 
unannounced visitation by the inspectorate division of the Irish Mental Health 
Commission (MHC) within the previous year. The service was therefore keen to 
improve its work in relation to clinical care pathways prior to the next visit by the 
commission. 
 
The choice to carry out this change project was therefore not a difficult one. Firstly, 
there was a genuine need for change, at service level, from both operational and 
strategic perspectives. Secondly, it was expected that the change would be cost neutral 
in that the efficiency and utilisation of existing resources might only require to be 
optimised. Thirdly, the author was in a vantage position of influence with favourable 
expert and position powers (French & Raven, 1959). 
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1.6. Expected Organisational Impact 
On successful completion, this project was expected to have a wide range of positive 
effects across all stakeholders. Patients were expected to experience improved quality 
of care that would hopefully translate to considerably enhanced quality of life. With 
increased awareness of their modifiable risk factors, they would become active 
participants in their own healthcare and well being. Staff would be empowered with 
new skills, enhanced professional confidence, job satisfaction and career progression. 
With established compliance with best practice guidelines, the service was expected 
to become less susceptible to complaints, clinical incidents and litigations. 
 
1.7. Summary  
This chapter has provided an overview of what this change project entailed and the 
context within which it was initiated and completed. The goal of planned change is to 
improve operational and managerial effectiveness. In this regard, the potential 
benefits not only for the patient but also for the staff and entire organisation as a 
whole has been outlined. The next chapter will provide a literature review on the 
clinical use clozapine while the subsequent chapters will focus on the method of 
change implementation, evaluation of the project and a discussion on the highlights 
of the project.  
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2. CHAPTER 2: LITERATURE REVIEW   
 
2.1. Introduction  
This chapter will explore the evidence base for the use of clozapine in treatment 
resistant schizophrenia. It will outline the mechanisms by which clozapine exerts its 
clinical effects, both therapeutic and harmful. A detailed discussion will follow on 
the adverse effects of clozapine and the recommended monitoring mechanisms aimed 
at improving the safety profile of the drug. The chapter concludes by highlighting the 
gaps in current service provision that formed the basis for this quality improvement 
initiative. 
 
2.2. Literature Search  
A comprehensive literature search was conducted on electronic databases including 
Pubmed, PsycINFO, Cochrane Library as well as the Psychology and Behavioural 
Science Collections. Further search was carried out using Google web search and 
Google Books. Relevant articles were filtered and reference lists were reviewed for 
supplementary sources. The following key words ‘clozapine’, ‘monitoring’, 
‘metabolic syndrome’, ‘schizophrenia’ and ‘physical health’ were included in the 
search both singly and in various combinations. Furthermore, international and 
national policy documents (in English Language) were searched for relevant 
information on the subject. Overall, there was considerable amount of relevant peer-
reviewed articles published on clozapine and its clinical effects, both therapeutic and 
adverse. 
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2.2.1. Schizophrenia and Treatment Resistance 
The term schizophrenia was coined by Eugene Bleuler in 1911. Prior to this, 
reports of people suffering from symptoms suggestive of the illness had been 
recorded as far back as the second millennium BC (Bleuler, 1911). 
Schizophrenia is a severe mental illness which affects one percent of people at 
some point in their lives (DSM-IV, 1994). In an Irish context, this prevalence 
rate approximates the number of people required to fill the capacity of Aviva 
Stadium™. Schizophrenia is a complex illness with a wide variety of 
symptoms, of which any particular person may only show a selection. These 
symptoms fall within two broad categories – positive and negative (DSM-IV, 
1994; Sims, 2002). 
 
Positive symptoms of schizophrenia include delusions (strange beliefs that 
cannot be shaken by logic or reason), hallucinations (usually in auditory 
modality, where the person hears voices that are not there), paranoia (in which 
the person believes people, etc are plotting against them), and thought disorder 
(abnormalities of the way thoughts are linked together as expressed in speech 
or writing) (Sims, 2002). These symptoms generally respond well to treatment 
although they can be quite dramatic and frightening for both sufferers and 
their carers. 
Negative symptoms develop more slowly and later in the course of the illness 
(Sims, 2002; Velligan & Alphs, 2008). They include social withdrawal, 
difficulties in communicating, lack of motivation and inability to cope with 
demands of everyday life like washing and dressing. Unfortunately, negative 
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symptoms do not respond as well to treatment (Smith et al, 2010); and can 
cause significant distress for both sufferers and their families who become 
frustrated by their lack of spontaneity and emotional response. 
 
The mainstay of treatment for schizophrenia is antipsychotic medications; 
usually as part of a holistic treatment plan (NICE, 2010). About 25% of people 
recover fully over a few months; a further 50% recover somewhat, albeit with 
recurring episodes of illness for the remainder of their lives while the final 
25% do not respond to conventional medical treatment and would suffer with 
enduring mental distress (Schizophrenia Ireland). This last group of patients 
are said to exhibit treatment resistance, defined as failure to respond to at least 
two conventional antipsychotic medications prescribed at appropriate doses 
over an appropriate duration (NICE, 2010). Due to problematic adverse effects 
associated with clozapine, the license for its clinical use has been restricted to 
this last cohort of sufferers (NICE, 2010).  
 
2.2.2. Role of Clozapine 
Clozapine was first developed by Sandoz® in 1961 but was introduced in 
clinical practice in 1972 (Crilly, 2007). Three years later it was voluntarily 
withdrawn by the manufacturers after the drug was conclusively linked with 
incidents of agranulocytosis which was unfortunately fatal in some of the 
patients that received the drug (Healy, 2004). However following robust 
evidence of its superior efficacy in treatment-resistant schizophrenia (McEvoy 
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et al, 2006; Lewis, 2006), clozapine received a restricted license specifically 
for patients who experienced treatment resistance. The caveat for this license 
was that a strict process be maintained for ongoing monitoring of the 
haematological profile of patients, with particular attention to the potentially 
fatal agranulocytosis (FDA, 2005).  
 
Within the class of atypical antipsychotic agents, clozapine is unique with its 
superior efficacy for both positive and negative symptoms in resistant 
schizophrenia (Chandrasekaran, 2008). It has also been shown to reduce 
suicidality, tendency to substance misuse as well as violence and aggression. 
For example, a Cochrane review of 29 studies involving 2490 participants 
confirmed a comparatively favourable response to clozapine in measures of 
symptom reduction, number of relapses, treatment discontinuation and overall 
satisfaction (McGrath, 1999).  
 
2.3. Psychopharmacology of Clozapine 
 
2.3.1. Pharmacodynamics 
Despite its unique clinical effects, clozapine shares its chemical structure quite 
closely with four other antipsychotics namely Olanzapine, Loxapine, Zotepine 
and Quetiapine (Stahl, 2000). Although it is primarily a 5HT2A – D2 
antagonist, clozapine has one of the most complex profiles in 
psychopharmacology with a myriad of receptor affinity and binding 
properties. This explains, at least in part, its unique clinical profile particularly 
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with regard to its broad range of adverse effects (Malhi, 2010). While its 
Serotonin-Dopamine antagonist properties are responsible for most of its 
antipsychotic effects, majority of its adverse effects are caused by its 
antihistaminic and anticholinergics properties. For example, clozapine induced 
weight gain is due mainly to its antihistaminic binding properties, made worse 
by concomitant Serotonin-2C antagonist actions (Stahl, 2000).  
 
2.3.2. Pharmacokinetics 
Clozapine is readily absorbed after oral administration with peak plasma 
concentration achieved after about 2.5hrs following an oral dose (Stahl, 2000). 
It is extensively metabolised by the liver to Norclozapine, which itself is 
pharmacologically active. Because it is subject to significant first pass effects 
in the liver, induction of metabolism such as occurs with smoking means that 
smokers do require considerably higher doses of clozapine to attain the same 
plasma concentration as non-smokers (Stahl, 2000). This has significant 
implications in terms of incidence and prevalence of adverse effects which 
have been shown to correlate with administered doses (Melkersson, 2004). 
 
2.4. Adverse Effects of Clozapine 
Evidence now abounds that people with schizophrenia die prematurely (Browne, 
2000; Osby et al, 2000; Hennekens et al, 2005; Capassa et al, 2008; Metzer, 2010). 
They have a two to fourfold increased relative risk of premature death; with majority 
dying at least 10 years earlier than age matched controls (Brown, 1997; Joukamaa et 
al, 2001). For these patients, their illness, its treatment and their lifestyle choices all 
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contribute to this excess morbidity and mortality, two-thirds of which has been 
attributed to physical causes such as cardiovascular disease, respiratory disease and 
diabetes. Lifestyle choices such as poor diets, low rates of physical activity and 
increased likelihood to smoke cigarettes have also been shown to be significantly 
contributory (McCreadie 2003). In addition, of critical importance in the causation of 
their excess morbidity and mortality remains the role of antipsychotic medications, 
particularly Clozapine (Newcomer, 2005; Bolton, 2011).  
 
2.4.1. Clozapine and Metabolic Disorders 
Antipsychotic-related weight gain was first reported in the late 1950s 
(Baptista, 2008). Excessive body weight substantially increases the risk of 
morbidity from a number of physical illnesses (Rummel-Kluge, 2010). Weight 
gain, especially of the central obesity variety, is one of the cluster of risk 
factors (central obesity, hyperglycaemia, hypertension and dyslipidaemia) that, 
when present together, constitute Metabolic Syndrome (MS) (Malhi, 2010). 
When present, MS has been shown to result in a two to three-fold increase in 
cardiovascular disease mortality; five-fold increased risk to develop type 2 
diabetes and a two-fold increase in overall mortality (Lakka et al, 2002; 
Dekker et al, 2005; Eckel et al, 2005).  
 
Clozapine has the greatest efficacy of all antipsychotic medications for the 
treatment of schizophrenia (Malhi, 2010; Chandrasekaran, 2008). However, it 
induces the worst metabolic adverse effects (Metzer, 2010), and has been 
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associated with significantly higher rates of metabolic syndrome compared to 
conventional antipsychotics (Mitchell, 2012). For example, in a meta-analysis 
of 80 studies that examined antipsychotic-induced weight gain, clozapine 
treatment was associated with a typical weight gain of about 4.5kg over 
10weeks, the most of any antipsychotic drug (Connolly & Kelly, 2005). In a 
5year naturalistic study on the metabolic consequences of clozapine, 
Henderson and colleagues (2000) found that up to one third of patients on 
clozapine developed diabetes after 5 years of treatment. Similarly, Newcomer 
et al (2002) studied the abnormalities in glucose regulation during 
antipsychotic treatment of schizophrenia. They found that clozapine was more 
likely than conventional antipsychotics to increase plasma glucose and insulin 
following an oral glucose challenge. Other researchers have found that this 
increase in plasma insulin correlates closely with the plasma clozapine level, 
which is in itself closely related to clozapine dose (Melkersson, 2004). This 
high prevalence of diabetes in people receiving clozapine makes routine 
screening a necessity (Lamberti, 2005). Clozapine has also been associated 
with considerable increases in plasma lipid levels, with mean triglyceride 
levels doubled and mean cholesterol levels increased by 10% after 5 years of 
treatment (Henderson et al, 2000). Clozapine induced dyslipidaemia is 
treatable and early intervention has been shown to reduce morbidity and 
mortality (Durrington, 2003). 
 
To put the above in context, Fontaine and colleagues (2001) estimated the 
consequences of antipsychotic-induced weight gain and found that while 
clozapine saved 492 schizophrenic patients from suicide per 100,000 
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clozapine-patient-years; clozapine induced metabolic syndrome killed 416 
patients over the same period. Clozapine-induced metabolic syndrome is 
therefore a serious iatrogenic disease for which the clinician must take full 
responsibility.  
 
2.4.2. Haematological Adverse Effects 
Clozapine is a somewhat toxic drug that carries a box warning mainly in 
relation to its propensity to cause agranulocytosis (Munro, 1999). When 
agranulocytosis occurs, the body’s ability to make the white blood cells that 
fight infection is greatly reduced with the result that an infection as simple as a 
sore throat can become life-threatening. Fortunately, agranulocytosis is rare 
with the risk of death reported in the UK as 1 in 100 000 patients exposed to 
clozapine (Taylor, 2009). This risk is well recognised and currently well 
managed by several approved clozapine-monitoring systems designed 
specifically for the purpose (Norvatis, 2010) 
 
2.4.3. Other Adverse Effects 
Clozapine has several other adverse effects (Appendix 1). A vast majority of 
these are idiosyncratic and tend to occur early in the course of treatment. 
Careful monitoring of these is a crucial aspect of good clinical care, especially 
as most can be treated or favourably modified by dose adjustment or other 
simple measures (Mortimer, 2011).  
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Without underestimating the suffering caused by schizophrenia, and following 
from the above descriptions, the intolerability and adverse effects of Clozapine 
poses a considerable challenge to the quality of life of those who have to take 
it. Fortunately, most of these adverse effects are easily detectable and 
completely reversible especially if robust mechanisms are put in place to 
ensure their early detection and prompt institution of appropriate interventions 
when necessary (Mortimer, 2011). 
 
2.5. Clozapine Monitoring 
 
2.5.1. Practice guidelines and quality in healthcare 
Since the 2000s, there has been a proliferation of national guidelines for the 
medical care of people with major mental illness (De Hert, 2011). The 
effectiveness of these guidelines in improving clinical care standards has 
however escaped scientific scrutiny until recently (Tosh, 2010). There have 
been concerns that existing guidelines are generally devoid of clear mandatory 
recommendations (Pincus, 2007). Reports suggest that routine medical care 
for psychiatric patients remain often overlooked (Gul, 2006; Mitchell, 2012), 
with only modest improvement following the recent surge of best practice 
guidelines (Grol, 2001; Sheldon, 2004; Pincus, 2010). A large British study 
conducted one year after the NICE guidelines revealed a high prevalence of 
undetected and untreated metabolic risk factors - in their study of 1966 
patients, Barnes and colleagues (2007) found that screening rates were very 
low (for every one person with diabetes, one was missed; for every case of 
dyslipidaemia, seven were missed while for hypertension, four were missed). 
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Several barriers to guideline-concordant, evidence-based care have been 
described, including inadequate organisational support, clinicians’ reluctance 
to change and lack of clear lines of responsibility (Francke, 2008; Forsner, 
2010). 
 
2.5.2. Recommended Practice on Clozapine Monitoring 
The Clozaril® Patient Monitoring Service (CPMS) is a 24hr a day, 7days a 
week service provided by Novartis™ with the aim of optimising the safety of 
all patients receiving the drug in UK and Ireland (Norvatis, 2010). This ISO 
2000 certified service has its primary focus on the detection and management 
of agranulocytosis in patients receiving clozapine and has led to a 30% 
reduction in deaths due to this adverse effect alone (Norvatis, 2010). Other 
Pharmaceutical companies that produce the clozapine are obliged by the drug 
license to provide a similar monitoring service. 
The landmark Clinical Antipsychotic Trials in Intervention Effectiveness 
(CATIE) study in the United States identified significant deficiencies in the 
detection and management of metabolic risk factors in these patients 
(Nasrallah, 2006). In order to address the safety concerns relating to the 
metabolic effects of clozapine, the 2006 NICE guidelines for schizophrenia 
recommended that these patients receive appropriate physical healthcare, with 
regular monitoring of their relevant metabolic parameters.  
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According to NICE (2006), the monitoring requirements for patients who have 
been stabilised on clozapine are as follows: 
• In the first year of treatment: 
o Blood Pressure, Pulse, Temperature to be assessed at least 
on a weekly basis 
o Weight, Body Mass Index (BMI), Waist Circumference, 
Fasting Lipids, Fasting Glucose and/or HBA1c to be carried 
checked at baseline, 1month, 3months, 6months and 
12months  
o Liver Function Tests (LFTs) to be carried out at baseline 6 
months 
• After the first year of established clozapine treatment: 
o Blood Pressure, Pulse, Weight, Waist circumference to be 
monitored at monthly visits 
o LFTs, Lipids, Glucose, Urea & Electrolytes to be monitored 
6 monthly 
Of note, the greater intensity of monitoring in the first year reflects the 
increased incidence of problems in the first compared to subsequent 
years of treatment. 
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2.5.3. Current Practice 
An internal audit previously carried out by the author as a proactive quality 
improvement initiative revealed an absence of local policy and practice 
guidelines on clozapine monitoring. The study also found that when tests were 
carried out, the practice was ad hoc and opportunistic and there was no 
standard procedure to ensure that abnormal findings were adequately 
followed-up and addressed. Staff were unfamiliar with best practice guidelines 
on the subject area, and expressed uncertainty regarding the share of 
responsibility between psychiatry and primary care in relation to monitoring 
and managing adverse effects of psychotropic medications in general. On a 
positive note, staff were enthusiastic for supportive guidelines and 
infrastructure towards the optimal care of this vulnerable group of patients. 
However, as can be seen from the above, the mere introduction of guidelines 
is hardly sufficient to influence a change of practice. Thus the need for this 
managed change effort. 
2.6. Summary  
This chapter has provided an overview of the evidence base behind the clinical use of 
clozapine. The gap between best practice principles and current local practice has also 
been highlighted. Because of its unique position in the treatment of schizophrenia, the 
adverse effects of clozapine deserve more than a cursory acknowledgement of their 
existence. The next chapter will therefore focus on the concept of change and its 
management. It will also provide a description of how modern change management 
principles were applied in implementing evidence-based practice in relation to the 
clinical use of clozapine within this mental health service.  
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3. CHAPTER 3: METHODS 
 
3.1. Introduction 
 
This chapter provides an overview of change from an organisational perspective. It 
discusses the concept of change management, and gives some insight into external 
and internal dynamics that can be of importance at times of organisational change. A 
critical appraisal of the various change models is followed by an explanation of the 
rationale behind the choice of the HSE change model to guide this project. The 
change process carried out is then described in detail using the HSE change model as 
a guiding tool. The chapter concludes with a summary of its highlights. 
 
3.2. Organisational Change 
The Oxford English Dictionary defines change as ‘an act or process through which 
something becomes different’. From an organisational point of view, Jones (2001) 
defined change as a process by which an organisation moves from its current position 
to some future position for the purpose of increasing its overall effectiveness. Three 
points stand out from Jones’ definition. Firstly, organisational change is goal 
directed; secondly it is future oriented and thirdly it is aimed at enhancing 
effectiveness and efficiency. Consequently, organisational change can be considered 
inseparable from organisational strategy, and vice versa, (Burnes, 2004; Rieley & 
Clarkson, 2001). 
Kotter and Schlesinger (2008) studied reactions to change and found that people’s 
emotional responses fall along a continuum from aggressive resistance to sincere 
embrace. According to Crozier & Friedberg (1980), resistance is a reasonable and 
legitimate expression of the risks which change entails for all who are affected by it. 
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Having said this, resistance is only one of the many challenges encountered in 
change. According to Senge et al (1999), these challenges come under three broad 
categories namely: (i) challenges of initiating change; (ii) challenges of sustaining 
momentum; and, (iii) challenges of system wide redesign and rethinking.  
 
3.3. Change Management 
Change management involves the ability to successfully guide change and is often 
the ultimate test of effective leadership. According to Todd (1999), it entails a 
structured and systematic approach to achieving sustainable change in human 
behaviour within an organisation. It can also be described as the planning, 
initialising, control and stabilising of change processes at both personal and 
organisational levels (Carnall, 2003). Change management is a core managerial 
competency (Senior, 2002). Graetz (2000) took an even stricter view on this by 
suggesting that the primary task of management in contemporary times is the 
leadership of organisational change.  
 
3.4. Change Models 
Several change management models have been described, all acknowledging change 
as a multi-step process. Although certain essential steps appear to be common across 
models, change is not predictable and hardly follows the exact steps that change 
management models suggest. The choice of model is therefore a matter of personal 
preference, but must take full cognisance of the context in which the change is to 
occur.  
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Examples of change models described in literature include Kurt Lewin’s model 
Lewin, 1951); Kotter’s change model (Kotter, 1995); Young’s model (Young, 2009) 
and the Health Service Executive (HSE) change model (HSE, 2008). Some of these 
are discussed in more detail below. 
 
3.4.1. Lewin’s Change Model 
 
Kurt Lewin (1890 – 1947) is credited for some of the earliest systematic 
studies on planned change, especially from a group or organisational 
perspective. Two of his hypotheses remain relevant to current thinking on 
organisational change: the idea that organisational or group processes are 
maintained at a state of equilibrium by a forcefield consisting of opposing 
forces; and the conceptualisation of change as a three-stage process namely 
unfreezing, change and refreezing (Lewin, 1951). Lewin also emphasised the 
contextual nature of change as well as the impact of group dynamics on 
individual responses to change. More recently, however, Lewin’s work has 
received criticism for its simplicity and linearity (Dawson, 1994); its greater 
applicability to incremental rather than transformational change (Dunphy and 
Stace, 1992); its heavy top-down, management-driven approach (Wilson, 
1992; Dawson, 1994); its limited attention to the influence of power and 
politics (Wilson, 1992; Dawson, 1994) and its lack of dynamism (Kanter et al, 
1992). However, some have argued that these criticisms are based on a rather 
narrow interpretation of Lewin’s work (Hendry, 1996; Ritchie, 2006; Longo, 
2011). 
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3.4.2. Kotter’s Change Model 
 
John P. Kotter, a professor at Harvard Business School, proposed an 8-step 
iterative process for implementing successful change (Kotter, 1995). Kotter’s 
model is not radically different from that of Lewin described above. Rather, 
the 8 steps arguably represent an elucidation of the nuanced elements in 
Lewin’s model, merely making these more explicit. These range from 
“creating a sense of urgency” (Unfreezing) to “anchoring” the changes 
(Refreezing). While Kotter’s model has been hailed for breaking up change to 
small manageable steps, others have argued that it is overly prescriptive and 
does not allow for the often necessary between-step flexibility within the 
change management process (Sidorko, 2008).  
 
3.4.3. HSE Change Model 
 
The Irish Health Service Executive (HSE) recognises change as a constant 
feature of health and social care service delivery (HSE, 2008). The HSE 
change model (Figure 1) was thus developed, in 2008, with the aim of 
improving the experience of patients and service users by facilitating a 
consistent and effective approach to change across the entire system (HSE, 
2008). Key attributes of this model include its basis on an organisation 
development approach, and its emphasis on the people aspects of change. It 
combines elements of project management to instil structure and discipline to 
the change process. It also places a strong value on active collaboration with 
stakeholders at every stage of the change process (HSE, 2008). The HSE 
model was selected to guide this change project because it was originally 
developed with due consideration to the HSE organisational framework of 
which this Community Mental Health Service is part. By approaching change 
as a cyclical and iterative process with between-steps flexibility, the HSE 
model easily lends itself as an invaluable tool for inculcating an ethos of 
continuous quality improvement. 
 
 
Fig. 1: HSE Change Model (HSE, 2008) 
 
3.5. The Change Process 
 
The four stages of the HSE change model include 
• Initiation 
• Planning 
• Implementation 
• Mainstreaming  
The application of these steps to the change management process is now described in 
more detail. 
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3.5.1. Initiation 
 
The key task here was preparing to lead the change. The focus was on putting 
forward a considered case for change; assessing and optimising readiness; 
establishing a sense of shared responsibility and building a solid foundation to 
drive and sustain the change effort (HSE, 2008). Personal and collective 
capacities for change were assessed and optimised by careful attention to 
factors that could potentially aid or impede the change effort. Similarly, an 
analysis of the people or groups that were likely to be impacted on by the 
process helped in creating a business case for change.  
 
Forces at play – drivers and resistors 
The initial stimulus for this change initiative was the author’s special interest 
in the interface between psychiatry and medical disorders, and particularly 
their empathic disposition to the adverse effects of psychiatric medications. 
This interest was further enhanced by an unannounced visit by the MHC 
inspectorate division in the previous year when the service came under 
criticism in relation to clinical care pathways, especially in the areas of 
physical examinations and general health promotion. Because a revisit of the 
inspectors was envisaged within the coming year, the synergistic effect of an 
external policy environment and an internal need to improve the work of the 
service in this subject area became a potent driver for change. Other notable 
driving forces included the position and expert power of the author, the 
healthy team dynamics within the service and the existence of other parallel 
but supportive change initiatives that were ongoing as part of a wider 
reconfiguration of the service model. Opposing factors (resistors), on the other 
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hand, included the potential for change fatigue, the perceived fear of increased 
work-load and the potentially paradoxical effect of the position and expert 
power of the author. 
 
Identification of Stakeholders 
Health service organisations are notorious for their complex structural 
frameworks, multi-cultural dispositions and delicate group dynamics. To this 
is added the equally diverse and complex external environment (community) 
within which a typical service operates. It was therefore considered essential 
to map out the key stakeholders from both within and outside the organisation; 
and to determine the opportunities and potential concerns that the change 
effort might bring to them.  
 
A stakeholders’ analysis (Polonsky & Scott, 2005, HSE, 2008) was carried out 
in which stakeholders were mapped into internal and external groups on the 
basis of their relative influence and interest in the change. The essence of this 
exercise was to form an objective basis for the development of a 
comprehensive strategy for effective reach-out and communication; and to 
ensure receptive reaction and sustained commitment over the course of the 
proposed change (HSE, 2008).  
 
For example, using the resulting power-interest grid (Appendix 2), the hospital 
senior management team, consultant psychiatrists, nursing management and 
local GPs were identified as the key stakeholders that required to be managed 
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closely. On this basis, the following communication channels were developed 
and sustained throughout the course of the change: 
• Progress report was placed as a recurring item on the agenda of the 
monthly Senior Management Team meeting (which the author/change 
leader was a member). Of note, the Director of Nursing was also a 
member of this team. 
• Progress report placed as a recurring item on the agenda of the monthly 
consultants’ Peer Review meetings (also attended by the author/change 
leader). 
• Regular feedback sessions to GPs at the monthly Primary Care Liaison 
meetings usually attended by the author/change leader and the 
Assistant Director of Nursing (also member of change team). 
• Progress report on the project was also scheduled as a regular item on 
the weekly MDT meeting agenda. 
 
Readiness and Capacity for change 
Readiness and capacity for change are similar and related concepts. An 
understanding of both is essential in identifying appropriate ways to support 
people through change (HSE, 2008). Readiness is a measure of openness to 
embrace change and is closely aligned to organisational culture, interpersonal 
relationships and intra-group dynamics. Capacity on the other hand relates 
closely to the organisational commitment to resource the change both at 
individual and corporate levels (HSE, 2008). 
The change leader rated key stakeholders for readiness and capacity using the 
Readiness-Capacity Assessment Chart (Beckhard & Harris, 1987). A high 
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rating was recorded in most areas of capacity for change while a medium 
rating was recorded for readiness for change. Much of the deficits in readiness 
arose from perceived lack of knowledge, and staff’s reluctance to leave their 
‘comfort zone’ (Kotter, 1996).  Because readiness pre-empts potential 
resistance, this finding provided an invaluable basis to recognise targets for 
extra motivation and support, especially at the outset, but also throughout the 
course of the change process. 
  
SWOT Analysis 
This is a useful tool for operational and strategic planning. It enables an 
evaluation of the Strengths, Weaknesses, Opportunities and Threats that are 
involved in an organisational venture; thereby crystallising the internal and 
external factors that may be favourable or unfavourable to achieving set 
objectives (Panagiotou, 2003). Used correctly, this tool helps with the 
identification of competitive advantage for any organisation (Jyothi et al, 
2008). At the second interactive group meeting, a SWOT analysis carried out 
by the team (Appendix 3) contributed immensely to developing a robust 
project implementation plan. 
 
Cultural and Political factors 
Cultural and political factors can significantly impact on the process and 
outcome of change (McAuliffe & Van Vaerenbergh, 2006; HSE, 2008). 
Understanding and managing organisational culture has a key role in 
formulating strategy or planning change (HSE, 2008). Culture can often be 
difficult to discern, both from within and from without the organisation. This 
29 
 
is due in part to the iceberg phenomenon described by Schein (1964), but can 
also be due to the high prevalence of subcultures that lie alongside the 
dominant culture within any organisation. 
 
In descriptive terms, the prevailing culture at this mental health service 
conformed to ‘role’ culture as described by Handy (1985) or ‘networked’ 
culture of Geoffee & Jones (1996) both of which are typically found in 
healthcare organisations. In practical terms however, there was a culture of 
trust and openness within groups, although territorial behaviour remained 
prevalent, especially between doctors and nurses. A lot of socialisation took 
place during work hours so avenues such as tea or smoking breaks were 
utilised by the change leader as opportunities to exert influence. Also, because 
group loyalty to key figures was prevalent; the change leader developed a 
good relationship with key line managers and this was used effectively in 
promoting change. 
 
In a typical ‘role’ culture, formal lines of communication are maintained and 
job descriptions rather than individual skills and abilities are sacrosanct. Also, 
strict adherence to principles and procedures rather than pragmatism or 
inventory is valued and rewarded (Handy, 1985). Careful attention was paid to 
these factors. Firstly, efforts were made to reinforce the rigid lines of 
communication by ensuring that social avenues were exploited for exchanging 
information and exerting influence. In this regard, caution was exercised on 
the position and expert powers (French & Raven, 1959) of the change leader. 
Secondly, there was a realisation of the need to enshrine the new standards and 
procedures within the performance appraisal and supervision process of all 
staff involved in running the clozapine clinic. This was expected to help 
stabilise change in the long term.  
 
 
Fig 2: Geoffee & Jones Matrix (Google Images) 
 
Assessment of Change Impact 
An initial assessment of the potential impact of the change was carried out at an 
organisational level. This exercise provided further insight into the relative 
amount of attention, planning and resources that the change will require, and 
what aspects of the organisation that will be impacted by the change. From this 
exercise, a project impact statement was generated (Appendix 4).  
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Objectives and Outcomes 
Objectives are specific statements of outcomes. They represent a clear and 
concise vision of what the change portends and must be communicated 
effectively if the change process is to succeed. They help to give direction to the 
change process, enhance the sense of urgency and promote cohesiveness amongst 
the guiding coalition or change team (HSE, 2008). Initial objectives and intended 
outcomes for this change project were derived by the change team from the 
project impact statement.  These were further streamlined and fine-tuned by the 
group to make them SMART (Specific, Measurable, Achievable, Realistic and 
Timely) and easy to communicate. The specific objectives of the project were as 
follows: 
• To develop a local policy guideline on clozapine monitoring that will 
be consistent with international best practice guidelines 
• To implement ongoing compliance of the service with evidence-based 
practice in relation to clozapine monitoring 
• To enhance the knowledge, attitude and practice of staff in relation of 
clozapine monitoring 
 
Business case for change 
The activities carried out in this initiation phase were synthesised into a 
business case for change. The essence of this exercise was to provide an 
objective basis and a compelling argument for a broad-based approval and 
support for the change. It also provided a reference document for tracking 
progress during the course of the change project (HSE, 2008). Careful 
consideration was given to the content and delivery of the business case to 
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ensure that stakeholders were clear on their roles, interests and potential 
challenges during the course of the change.  
 
3.5.2. Planning  
 
In this phase, specific details of the change were determined and 
communicated with a view to garnering support for the process. Creating this 
support ensured that people were carried along with a harmonised view of the 
new future for the organisation (HSE, 2008). This phase ushered in the first 
visible actions regarding the change initiative. Commitment was established 
on an organisation-wide basis; initial momentum was generated and capacity 
for change was optimised. The 7s model (Figure 3) conceptualised by Waters 
and Peterman (1982) enabled due consideration to be given to the various 
elements of the organisational framework during the planning and 
implementation of the change. The model provided an invaluable frame of 
reference for establishing a baseline and adopting a whole-organisation 
approach in managing the change process. Every change process has its 
complexities and challenges. The cornerstone for success in this phase was 
communication - there could never have been too much of it. The phase 
entailed three iterative steps, namely (HSE, 2008): 
• Building commitment 
• Determining the details of the change, and 
• Developing the project implementation plan 
 Fig. 3: The McKinsey’s 7s Model (Waters & Peterman, 1982) 
 
Building Commitment 
Lewin (1951) was passionate about the role of group dynamics in 
organisational change. He believed that group procedures for changing 
attitudes or behaviours were effective because people tended to respond as 
group members rather than follow their own individual preferences. He 
hypothesised that “it is usually easier to change individuals formed into a 
group than to change any one of them separately” (Lewin, 1951). The HSE 
change model (HSE, 2008) also acknowledged group dynamics within its 
ethos of an organisational development approach and its focus on the people 
and cultural aspects of change.  
Interactive group meetings are effective in changing behaviour; with their 
degree of interactivity correlating well with effectiveness in changing 
behaviour (NICE, 2007). While conferences and lectures raise awareness 
about desired change, they are often less effective in making change happen 
(NICE, 2007). It was in these contexts that the change leader adopted a group-
33 
 
34 
 
based approach in dealing with the change team especially during this early 
part of the project.  
 
In building commitment, the key task was to inspire an appetite for change by 
clearly communicating the vision and demonstrating that change was 
underway. The change leader commenced this process by presenting the 
results of the internal audit to members of the MDT initially and subsequently 
in more detail to staff of the clozapine clinic. The emphasis on the clozapine 
clinic staff was because they were the people that were to be most affected by 
the change.  
 
Awareness and conviction on what needs to change, and why, are crucial first 
steps in enabling change to occur. Healthcare professionals often lack 
awareness of, and/or familiarity with latest evidence-based guidelines. When 
they do, they may be unaware of what needs to change to bring their practice 
to compliance with these guidelines (NICE, 2007). The author observed that 
discussing the findings of the internal audit with the team in an interactive and 
non-coercive manner inspired an intrinsic desire for change, going by the 
spoken and unspoken comments and gestures evident at the end of the 
meeting. Thus, the earliest foundations for commitment to change were laid. 
 
The audit findings were subsequently presented to the Senior Management (of 
which the change leader is member) at their next sitting. The presentation took 
cognisance of the broader contexts of the recent visit and findings of the MHC 
inspectorate and the implications for the service of their imminent revisit to 
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assess progress on identified failings. A business case for change was 
proffered and unanimously adopted by the group. The group became the 
guiding coalition for the change.  
 
Determining the Detail of the Change 
This step involved assessing the current situation, determining the finer 
elements of the change that needed to occur and outlining what available 
resources will support the change process (HSE, 2008). A further meeting was 
held with the MDT to communicate the ratification of the change initiative and 
to determine the specific next steps. A small-group, problem–solving approach 
was adopted for the meeting. Details of the audit findings turned out a very 
useful resource in terms of clarifying the status quo.  
 
Brainstorming  
A broad-based brainstorming session involving all MDT members, 
administrative staff and a representative of a patient’s advocacy group instilled 
rigour to the planning process. One advantage of brainstorming is that 
participants can bounce ideas off each other, and further develop and refine 
these (NICE, 2007). Besides providing a means of developing creative 
solutions to the potential challenges ahead, brainstorming also facilitated 
active participation of team members in the formative stages, thereby fostering 
a sense of ownership of the process. 
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Journal Clubs 
Following from the above; the change leader reflected on the process and 
outcome of the interactive, problem-based group meetings and undertook self-
directed learning to fill gaps in personal knowledge that became apparent from 
questions and opinions expressed by staff during the meetings. Subsequently, 
four (weekly) journal clubs were facilitated for the team by the change leader 
with the aim of appraising recent literature and evidence-base on international 
best practice in the area. The value of evidence-based journal clubs in 
facilitating postgraduate learning has been well documented (Ebbert, 2001). 
These journal clubs were therefore chosen as the primary approach towards 
enhancing the knowledge of staff in relation to the safe clinical use of 
clozapine, as set out in the study objectives. 
 
Process mapping 
Visual descriptions of the flow of activities at the clozapine clinic were 
designed; for both the current practice and the desired future practice 
(Appendix 5). The variance between the two maps helped to crystallise the 
work that needed to be done to effect successful change. Process mapping is a 
powerful tool that can be used for determining the underlying causes of 
performance problems and identifying performance improvement needs. Once 
a process is mapped, it is easy to spot omissions, redundancies, insufficient 
work support, ineffective communication and all other obstacles that may 
impede effectiveness and efficiency (West, 1997; Marrelli, 1998).  
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The change team 
It was during this phase that the change team was agreed. The change team 
comprised of a Consultant Psychiatrist (author, change leader); Psychiatric 
Registrar, two nursing staff from the clozapine clinic, Clinical Nurse Manager 
of Day Hospital (where clozapine clinic is based) and the Assistant Director of 
Nursing (ADON).  
 
Proforma development 
The next task undertaken was the development of proforma for documenting 
the findings of physical examinations and laboratory investigations conducted 
at clozapine clinic visits. It was considered that a single document that 
highlighted the relevant parameters would be most ideal. As there was no such 
document available from literature search, the team developed one de novo, 
with due reference to current evidence-base, during one of their interactive 
sessions. This draft was presented by the author to peers at the February 2012 
Action Learning Set (ALS) where it received positive feedback. There was 
however advice to provide space for the signature of assessor, and also to 
consider printing the form on coloured paper to enhance its visibility within 
the often bulky patient medical records. These suggestions were unanimously 
adopted by the change team as reflected in the final version of the proforma 
(Appendix 6). 
 
A standardised letter format was also developed to serve as a clear and concise 
way to promptly communicate any identified abnormalities to the patient’s GP 
(Appendix 7). The initial draft of this received good feedback from peers at 
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the 2nd ALS and was also unanimously endorsed by GPs when it was 
presented to them during a primary care liaison meeting. 
 
Developing the Implementation Plan 
More detailed design of the change was undertaken at this phase, with careful 
attention paid to specific details of the process. The broad-based 
interdisciplinary group referred to above were once again consulted. Details of 
the objectives, process and potential impact of the project on all stakeholders 
were revised. People were encouraged to voice their fears and concerns and 
gentle reassurance and support were provided where necessary. The change 
leader remained cognisant of Cartwright and Baldwin’s (2007) view that the 
change agent’s ability to communicate, their skills of negotiation and the 
expert power they posses all play a crucial role in the success or otherwise of 
any change effort. 
  
Scope of the change 
The start date (01/03/2012) and implementation time frame (six weeks) was 
agreed and communicated widely. It was also agreed that the change will be 
focused on adverse effects of metabolic syndrome, albeit with attention to the 
various other idiosyncratic effects of clozapine. All documents containing 
clinical information on patients taking clozapine were to be amalgamated into 
the main patient medical record. Abnormal findings were to be communicated 
to patients’ GPs using the standardised letter described above. It was also 
agreed at this point that the change team would meet for a quarter of an hour 
after the weekly MDT meetings throughout the course of the change. This was 
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with a view to ensuring regular updates, feedback and support during the 
change. 
  
Sequence of change steps 
It was agreed that all existing patients on clozapine (n = 32) would be invited 
for initial physical examination and laboratory tests to serve as baseline 
parameters for future reference. Eight patients were to be reviewed per week, 
with all expected to be seen over four a four week period. Subsequently, the 
monitoring exercise was to be carried out in compliance with the NICE (2006) 
guidelines described above. Development of a local policy on the monitoring 
of patients on clozapine was scheduled to be done serially during the weekly 
meetings of the change team. Post change evaluation was scheduled to take 
place at the end of the 6th week. 
 
Resource requirements 
Structural changes were resource neutral as existing staff and equipment were 
utilised within their effective capacity. Two new tapes for measuring 
abdominal and waist circumferences were procured while the existing BP 
measuring apparatus, weight/height measuring scale and clinical thermometer 
were examined to ensure good functional state. 
 
 
3.5.3. Implementation 
 
The focus of this step was to apply the agreed changes to the structure and 
process of care, paying careful attention to the factors that will promote 
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favourable outcomes and long term sustainability. Residual resistance often 
becomes apparent during this step. According to Armstrong (2001), the shock 
of the ‘new’ way may cause insecurities in people who are afraid to lose their 
familiarity and sense of belonging. In this regard, the change leader ensured 
relentless communication with the change team and other key stakeholders 
with a view to sustaining momentum and keeping focus on the vision and 
goals of the change. 
 
The team kept to the agreed commencement date and the response of the first 
batch of patients for physical health screening was quite encouraging. One of 
the clozapine clinic nurses expressed unease about the mildly “invasive” 
nature of some of the physical examination procedures including measurement 
of the waist/hip ratio using a measuring tape. This concern was successfully 
addressed through reassurance and support from both the change leader and at 
peer level. Abnormal findings were uncovered in three out of the first eight 
patients and these were further reviewed by the consultant psychiatrist (change 
leader). Of these, two patients required further attention by their GPs and were 
referred accordingly using the standardised letter developed for the purpose 
(Appendix 7). 
 
The remaining three weekly sessions of baseline tests were completed 
uneventfully. Staff had become more confident and appeared to be coping 
reasonably well with the demands of the new practice. Fourteen other patients 
required referral to eight different GPs for further assessment and treatment. 
These referrals were followed up by their key workers who remained in close 
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liaison with the GPs to ensure adequate follow-through and information 
sharing on their treatment. Seven of the GPs accepted their new roles without 
expressing concerns. Indeed, one of them wrote a letter expressing delight at 
the improved information sharing on the physical health of their patients who 
were under shared care with the mental health team. This positive feedback, 
along with several others from patients and their carers were acknowledged as 
short term gains and were used by the change leader to promote and sustain 
momentum on the change. However, one of the GPs was reluctant to take up 
the new responsibility, citing increased workload as his concern. Strong 
resistance to change is often rooted in deeply conditioned or historically 
reinforced feelings. This underscores the need for patience and tolerance in 
helping people in these situations to see things differently and to embrace new 
approaches. This act of resistance was successfully addressed by the change 
leader by engaging the GP in one-to-one sessions and providing him with 
more information and support.  
 
The ADON oversaw the printing of proforma on coloured paper as agreed. 
The new proforma were properly filed, by the team administrative staff, within 
the patient case notes in line with HSE policy and guidelines on proper 
keeping of patients’ medical records. Regular feedback on the change process 
was provided to the Senior Management Team, Consultants’ peer review 
meetings and the weekly MDT meeting at the Day Hospital.  
 
Because change involves a series of iterative events, sustaining momentum 
and energy is essential. With this in mind, the change leader engaged staff, 
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using a wide range of avenues, both on an individual and group basis. This 
was aimed at providing support, acknowledging challenges and encouraging 
expressions of alternative opinions where available. All reactions; positive or 
negative, verbal or non-verbal were given due consideration. Negative 
reactions were quite minor, and were merely around uncertainties regarding 
the proper filling of the monitoring proforma. These were addressed by 
information sharing, encouragement and support. Positive feedbacks however 
were plentiful, coming mainly from patients and their families, but also from 
GPs, change team and wider MDT members. These were highlighted as short 
term gains and served to inspire greater commitment to the cause.  
 
3.5.4. Mainstreaming 
  
Here, the focus was on integrating and sustaining the new practice; evaluating 
the change process and promoting continuous improvements. Ensuring that 
new practices and behaviours are rooted in social norms and shared values 
ensures that they do not regress as soon as the pressure for change is removed 
(HSE, 2008). Similarly, evaluating the project facilitates active learning from 
the process, while providing an objective basis for further service development 
initiatives, within the true spirit of change as a continuous and cyclical 
process. 
 
3.5.4.1. Embedding the change  
 
To make the new practice “the way we do our business” (HSE, 2008), 
the change leader adopted two approaches namely: 
• Linking new work practices to improved performance, and 
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• Making adherence to new work practices relevant to regular 
performance reviews 
Under the first approach, efforts were made to demonstrate to key 
stakeholders how the new work practices were linked to ongoing 
compliance with best practice guidelines and reduced susceptibility of 
the service to complaints and litigations. Helping people to establish 
such links is expected to have several positive effects, including: 
• Promoting a sense of ownership of the new process and its 
outcomes 
• Instilling a feeling of responsibility for ensuring the long 
term sustenance of the new work practice 
• Making it explicit how individual behaviours can be linked 
with any deterioration of standards in the future 
• Making people more open to change in the future  
 
The second measure was an attempt to ensure that the next generation 
of decision makers are people who embody the new approach and are 
open to continuous improvements. If the requirements for career 
progression do not change, renewal rarely lasts and old ways of doing 
things quickly re-emerge (HSE, 2008). Although this could be easily 
dismissed as a “stick” approach, it remains relevant that “what gets 
measured gets done” (Drucker, 1954). Consequently, the change leader 
successfully negotiated with the nursing hierarchy to institute 
adherence to the new practice as part of the regular performance 
review and appraisal system for nurses towards their continued 
professional development. The same was also agreed with the Clinical 
Tutor and Clinical Director in relation to the Psychiatric Registrar and 
Consultant Psychiatrist (change leader) both of whom would provide 
ongoing medical back-up to the clozapine clinic. The success of this 
approach depended somewhat on the formal, bureaucratic role culture 
(Handy, 1999) of the HSE of which this service is a part. Of note, the 
nursing staff welcomed this idea citing formal recognition of their 
personal efforts as a potentially strong motivating factor for future 
commitment to the cause. 
 
Fig 4: Handy’s Role Culture – designed after the Greek Temple for Apollo 
 
3.5.4.2. Evaluating and Learning 
 
To further embed the new work practice, it was essential to review the 
design and implementation of the change process. The primary goals 
of evaluation were to facilitate any necessary adaptations of the 
ongoing process towards improved outcomes, and to identify learning 
points that will inform the conduct of future change programmes. In 
choosing evaluation tools and approaches, due consideration was given 
44 
 
45 
 
to their validity and reliability, and efforts were made to ensure that the 
project objectives were properly aligned with evaluation outcomes.  
Evaluation as referred to here was conducted in its broadest context, 
including not only of the structure, process and outcome of the change, 
but also on a personal level by way of critical reflection. For ease of 
reference, further details of the evaluation and reflection aspects of this 
dissertation will be provided in the relevant chapters below. 
 
3.6. Summary  
 
Having first provided an overview of the extensive literature available on change and 
its management, this chapter has described the successful journey through a planned 
change effort using the HSE change model as a guide. Future evaluations that have 
already been scheduled as part of this change project will hopefully confirm the long-
term sustainability of the new work practice, while also providing objective bases for 
continuous quality improvements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
4. CHAPTER 4: EVALUATION 
 
4.1. Introduction 
 
Evaluation is a systematic and structured process of reviewing an experience with the 
aim of determining its value and deciding what could be done differently (HSE, 
2008). According to Lazenbatt (2002), it provides a means of measuring the extent to 
which a set of actions have achieved their objectives. Peter Drucker (1954) captured 
the strong correlation between evaluation and motivation in his now famous 
hypothesis that “what gets measured gets done”. Even though it is listed as a separate 
step within the HSE framework, the model recognises evaluation as vital to every 
aspect of the change process (HSE, 2008). This approach of evaluating in action not 
only has a strong formative impact on individual and organisational learning, it also 
allows for adaptations to be made at every point in the change process. Such 
adaptability and flexibility provided for within the framework of the HSE change 
model made it an easy choice for this project.  
 
The primary concern of evaluation is to determine the achievement of pre-defined 
goals. Rather than assume that implemented change is working, it is important that 
specific performance targets and measures are used to track and stabilise change 
(Moran, 2000). Two concepts are relevant here. The first is efficiency, a measure of 
the extent to which aims and objectives have been attained; and the second is 
effectiveness, a measure of the extent to which objectives have led to desired 
outcomes (Lazenbatt, 2002).  
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This chapter will address the evaluation of the change project in relation to its 
process and outcome. The tools and approaches chosen for the evaluation will be 
described along with the rationale behind their selection. It is important to note that at 
the time of writing this dissertation, the change cycle remained ongoing. However, 
significant and measurable achievements were already evident and making these 
explicit was considered essential to promoting and embedding the new approach.  
 
4.2. Evaluation Tools 
 
Various tools and approaches are available for the purpose of evaluation. In making 
choices between these, it is essential that due consideration is given to what is being 
measured and the context in which the measurement is to take place. Broadly 
speaking, evaluation can be approached from two distinct perspectives, namely 
qualitative and quantitative (Burns, 2000). Qualitative approaches are generally 
exploratory in nature and aim to provide insights, generate hypotheses or develop 
initial understandings on a subject. Sample sizes are usually small and data is 
collected using unstructured or semi-structured techniques including focus groups, 
individual interviews, etc. Analysis is on a non-statistical basis and reports are 
presented in descriptive terms. Quantitative approaches on the other hand are used to 
quantify data and generalise results from large samples. Data is collected using 
structured techniques such as questionnaires and checklists. Conclusive findings 
made from statistical analysis of such data may be used to recommend a final course 
of action. This project was evaluated using a combination of qualitative (focus 
groups, interviews) and quantitative (pre- and post change questionnaires, 
retrospective chart review) methods.  
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4.3. Evaluation of Project 
 
4.3.1. Qualitative Methods  
 
4.3.1.1. Focus Groups 
 
Focus groups involve an explicit use of group interaction to produce 
data and insights that would be less accessible without the interaction 
generated in a group setting (NICE, 2007). Typically, it involves a 
facilitator using a range of stimuli to generate discussion in an 
interactive, non-coercive group setting (NICE, 2007). The use of focus 
groups in this project had a powerful formative impact on its progress, 
and also contributed to the summative evaluation of its outcome.  
Three focus groups were facilitated altogether by the change leader 
during the course of the project – one at the initiation phase, the second 
at the planning phase and the last at the evaluation phase. The groups 
comprised of six members of the change team on the three occasions. 
The sessions were used to gain insights into the perceptions, opinions, 
attitudes and beliefs of team members on the various aspects of the 
change programme. Pre- and post- questionnaires were distributed at 
the end of the first and last sessions. These will be described in more 
detail under quantitative evaluation. The main value of the first two 
focus group sessions was in their formative effects on the change 
process, while the last session was weighted towards a summative 
appraisal of the process. A summary of findings of the last session is 
presented below. 
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Vision 
There was a shared agreement that the vision was valid, clear and 
coherently articulated. Members felt that it was reasonably easy to buy 
into and develop their own personal sense of ownership of the vision. 
 
Communication 
Every member of the team felt that communication was adequate. 
There was a shared appreciation of the use of both formal and informal 
avenues of communication by the change leader. In particular, one 
team member highlighted the importance of the “walking the talk” 
attitude adopted by the change leader. 
 
Team work 
There was a general appreciation of the consistent involvement of the 
group at every stage of the project. Members felt that their 
contributions, opinions and concerns were acknowledged and that they 
felt empowered and supported to take measured risks as part of 
learning their new roles. 
 
Cultural factors 
There was consensus that both inter-group and intra-group sensitivities 
were well handled especially in relation to the usual tensions that 
usually exist between the various professions due to their differing 
cultural orientations. However, one team member regretted that 
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hierarchical sensitivities were aroused during one of the sessions when 
some aspects of the process were challenged. 
 
Alignment of process with expected outcomes 
Staff generally agreed that the project implementation plan was 
appropriately designed to achieve the project goals. There was also a 
consensus that project timelines were realistic and adhered to through 
the course of the project. 
 
4.3.1.2. Interviews  
 
Interviews aim to elicit the responder’s perspectives by asking open-
ended questions, listening to and recording answers in an iterative and 
goal-directed fashion (Kvale, 1996). Here, the change leader 
conducted informal interviews with local GPs (n=8) and patients 
(n=32) to assess their perceptions of and satisfaction with the change 
process and its outcomes. GPs were contacted largely by telephone 
(n=6), with the remainder (n=2) interviewed on a face-to-face basis. 
Patients on the other hand were interviewed during their routine 
clinical visits. The vast majority of respondents expressed satisfaction 
with the process and outcome of the change. While the views of GPs 
can be taken on its prima facie value, the change leader remained 
cognisant that the responses of patients must be interpreted with 
caution as the power differential between patients and their doctors, 
especially in a mental health context, can lead to false positive 
responses and assumptions. 
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4.3.2. Quantitative Methods 
 
Pre- and post implementation questionnaires and a retrospective case note 
review constituted the quantitative evaluation tools used for this project. 
Questionnaires are useful for measuring whether a programme intervention 
has met its objectives. They allow for anonymity and can be used to collect 
vast amounts of data over a reasonably quick space of time. In addition, 
questions are standardised and can be easily analysed (Burns, 2000). A 
retrospective case note review, on the other hand, allowed for the 
measurement of the success or otherwise of the project to achieve its objective 
in relation to ensuring compliance with best practice guidelines for the 
monitoring of clozapine.  
 
4.3.2.1. Questionnaires  
 
An anonymous, self administered questionnaire was developed by the 
change leader based on literature review and in line with the project 
objectives. This questionnaire (Appendix 8) used five closed-ended 
questions with three set-response options to elicit the respondents’ 
opinions on their own knowledge, attitudes and practices in relation to 
monitoring adverse effects of clozapine. There was also a question 
regarding their interest and commitment to continuous quality 
improvements on this aspect of their practice. The questionnaires were 
distributed to team members at the beginning of the first and last focus 
group sessions, and were returned by being dropped anonymously into 
a box provided for the purpose at the end of the sessions. The response 
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rate of 100% was not surprising giving the small size and collegial 
nature of the sampled group and the influence conferred by the 
position power of the change leader.  Details of findings are provided 
in Appendix 9. In summary, there were significant improvements in all 
parameters that were measured. Of particular importance was the very 
high rating on “commitment to continuous quality improvement” 
which can be interpreted as an early sign of long term sustenance. 
 
4.3.2.2. Retrospective Chart Reviews 
 
Retrospective studies use existing data that would usually have been 
recorded for reasons other than research to measure specific outcomes 
(Dean, 2004). From a healthcare perspective, they are often referred to 
as chart reviews because the primary data source is invariably patient 
medical records. One of the objectives of this project was to implement 
compliance with best practice guidelines in relation to clozapine 
monitoring. A retrospective chart review was chosen to evaluate this 
because of its objectivity, as patients’ medical records were expected 
to provide reliable documentary evidence of clinical care.  
 
In this exercise, the medical charts of all patients on clozapine 
treatment (n=32) were retrospectively reviewed to assess whether or 
not they contained the proforma that was developed as part of this 
project, and whether these had been properly completed to reflect 
evidence-based practice. Data was collected using a checklist method, 
and analysed with descriptive statistics. The result of a 100% 
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compliance rate was, again, unsurprising giving the small sample size 
and the commitment of the team to the objectives of the study.  
 
4.4. Summary  
 
This chapter has provided an overview of the concept of evaluation from a healthcare 
management perspective. It has described the evaluation of the change project in 
terms of its process and outcomes using a range of tools and approaches. The findings 
which were consistently positive from across the range of tools became potent 
secondary drivers for stabilising the new practice and setting the tone for continuous 
quality improvements. Inferences drawn from these evaluations will form the basis for 
the discussion and reflection aspects of this dissertation in the following chapter. 
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5. CHAPTER 5: DISCUSSION 
 
5.1. Introduction  
 
This change project set out to implement evidence-based practice in relation to the 
monitoring of patients treated with clozapine by a community mental health service. 
A review of relevant literature and an in-depth account of the journey through the 
planning, implementation and evaluation phases of this change have been outlined in 
the previous chapters. This chapter will highlight the strengths and limitations of the 
project. This will be followed by recommendations for future service development 
based on inferences drawn from the project evaluation. The chapter will conclude 
with a critical reflection on the author’s experiences through the course of this 
project. 
 
5.2. Strengths of Project 
 
Scope of Change (within the core business of the service) 
Clinical care pathways are central to the work of any health service 
organisation. Recognition that the desired change had huge significance within 
the context of the primary task of the service made it easier to secure and 
sustain the engagement of key stakeholders during the course of the project. It 
also meant that people were not taken far out of their comfort zones, one of the 
commonest causes of resistance to change. 
 
Compelling Drivers for Change 
With the increasing emphasis on healthcare regulation, evidence-based 
practice and continuous quality improvements have grown from desirable to 
indispensable concepts. At service level, external policy requirements to 
comply with best practice guidelines increased the urgency and made the 
change somewhat inevitable. This type of scenario often arises in the 
organisational structure described by Henry Mintzberg (1994) as “Professional 
Bureaucracy” where external drivers, usually in the form of government or 
regulatory directives, provide the most potent drivers for change. 
 
Fig 4: Mintzberg’s model (after Sherwin, 2009) 
Expert & Position Power of Change Leader 
Raven and French (1959) described the potential influence conferred by expert 
knowledge and hierarchical position in organisational management. Again, 
this is particularly relevant in Professional Bureaucracies (Mintzberg, 1994). 
Cautious use was made of this potentially rich source of influence when the 
change leader bargained or negotiated with key stakeholders during the 
planning and implementation of the change. 
 
SMART Objectives 
Simple, Measurable, Achievable, Realistic and Timely (SMART) objectives 
are exactly what the acronym suggests. The concise and targeted nature of the 
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change objectives made it easier to carry people along and to maintain focus 
during the course of the change.  
 
Resource Neutrality 
This change required adaptations to the structure and process of care. In the 
current fiscal climate, cost-effectiveness can be both a reason for and an 
obstacle to change. In this project, care was taken to ensure that adaptations 
made were within the effective capacities of both personnel and equipments. 
In management parlance, the efficiency and utilisation of existing resources 
were merely optimised by adopting principles and tools of continuous quality 
improvement.  
 
Parallel Change Initiatives (Supportive) 
This change occurred in parallel with other quality improvement initiatives 
that formed part of a broader service reconfiguration programme. Some of 
these were particularly supportive, including ongoing introduction of 
individual care and treatment planning, integrated patient medical records and 
primary care liaison. 
 
5.3. Limitations of Project 
 
Small sample size  
Though it may be harsh to judge the evaluation of this project with the strict 
rigour usually applied to systematic research, the power of the studies in 
detecting real change would be compromised by the relatively small sample 
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size arising from the small number of staff directly involved in the change 
process. 
 
Expert & Position power of change leader 
The expert and position powers of the change leader described above could 
paradoxically lead to superficial commitment and covert resistance with 
implications for long term sustainability of the change. 
 
Time pressure 
There was subjective pressure to achieve tangible milestones for the purpose 
of writing a meaningful dissertation. The need to submit this dissertation 
within a limited timeframe also meant that further evaluations that would be 
carried out to confirm stabilisation of the change will not be reported here. 
 
Prior experience of managed change 
There was no abundance of prior experience of managed change efforts both 
at personal and service levels. However, this potential weakness did not 
appear to have impacted to any material extent on the success of the effort. 
 
Change fatigue 
As stated above, there was a host of parallel change initiatives within the 
context of a wider reconfiguration of the service model. Confusion, despair, 
lowered organisational productivity and passive resistance can all arise in 
these contexts. 
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5.4. Recommendations for Future Improvements 
 
The change described above has been implemented in one of four similar and 
adjacent geographically sectorised community mental health teams.  On the basis of 
the success of this change effort, it would be prudent from both clinical and 
management perspectives to embark on a planned and carefully managed roll-out of 
the new approach to the entire mental health service. At the wider service level, 
adherence to best practice guidelines such as was introduced with this change will 
reduce exposure to complaints and litigations from service users and their carers, as 
well as the likelihood of censorship from the MHC inspectors at their inevitable 
future visits to the service. 
 
In implementing the above recommendation, it is hoped that the service would 
benefit from the considerable experience gleaned by the staff involved in this project 
who have become a huge resource base as change champions. Incorporating elements 
of change management in the continued professional development curriculum of staff 
will provide a platform where the current change champions can share their learning 
and experience with their peers. Also, recognising and rewarding the achievements of 
current change champions will be an excellent way of implicitly and explicitly 
communicating what is valued; and in so doing help to embed the emergent culture 
of change. 
 
From clinical and academic perspectives, data generated from implementing and 
evaluating this change could provide a useful basis for future formal research into the 
incidence and prevalence of metabolic disorders and other physical health 
disturbances that arise from, or are incidental to clozapine and other pharmacological 
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interventions. Such findings can inform the development of future evidence-based 
guidelines both locally and internationally. Indeed, the service can become a centre 
of excellence in the whole area of the interface between psychiatry and mental 
disorders by building on the special interest demonstrated by the author in this 
subject area 
 
 
5.5. Reflection  
Experiential learning is at the core of lifelong learning (Kolb, 1984; Rogers, 1969). It 
refers to the process of making meaning from one’s direct experience. Here learning 
is constructed from experiences that arise in the context of work situations. It 
requires learners to focus on an experience; reflect upon it to understand it better; 
identify areas for further development; find solutions to new issues encountered and 
practice these solutions. Ultimately, the experiential learner is able to look back at an 
experience and its contexts in order to determine further action and reflection (Kolb, 
1984). 
 
Lifelong learning is no longer a choice for medical professionals; it is now both a 
necessity and an obligation. The skill of reflection is central to the twin concepts of 
experiential learning and lifelong learning. Reflection allows clinicians to use their 
day-to-day experiences to evolve and shape their practice. Reflective practice 
involves change. This change often derives from a discovery of; and adaptation to 
new knowledge. Both change and new knowledge can be painful. Emotional 
difficulties associated with critical reflection have been widely described 
(Brookfield, 1987; Mesirow 1990). These emotional difficulties arise because every 
change, even a change for the better, is accompanied by drawbacks and discomforts. 
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Challenging one’s own underlying assumptions in these circumstances can be 
unsettling as I soon discovered during this project. 
  
Looking back at this project, two particular factors had the most profound influence 
on the process and outcome of the change. The first was the conscious decision to 
adopt a group-based approach in dealing with the change team and entire MDT, 
particularly at the nascent stages of the change process. According to Lewin (1947), 
interactive, non-coercive group discussions where participants decide “among 
themselves” to adopt new behaviours are far more effective than expert lectures or 
one-to-one persuasion. Lewin argued that the reason why group procedures for 
changing attitudes and conducts are so effective is that people tend to respond as 
group members rather than on their individual preferences because of an inherent 
human desire to identify with group norms. In practical terms, this approach ensured 
an early buy-in by fostering a sense of ownership of the initiative, rather than it being 
perceived as imposed from above. To achieve this, it was important that I targeted 
both the “natural” and the “official” leaders within the group and maintained a 
cordial relationship with them to ensure that their influence was used positively 
during the course of the project.  
 
The second factor was the careful attention that I paid to the pros and cons of my 
expert and position powers. While these can confer considerable potential to wield 
influence within organisations, they can also lead to superficial commitment and 
passive or covert resistance. As discussed above, this type of influence can be 
particularly helpful in the cultural and structural frameworks seen in healthcare 
organisations. A practical example is an earlier experience in which I attempted to 
61 
 
implement a similar change while working as a psychiatric trainee in another service. 
Despite cogent rationale and urgency for change in that situation, it was difficult to 
sustain investment, enthusiasm, and engagement on the project due to differing 
priorities as seen by the top hierarchy of that organisation.  
At cognitive and emotional levels, my underlying attitudes of intellectual curiosity 
and openness to new experience became reinforced by the experience of this change 
project. Although my thoughts of carrying out this project were heralded with 
tremendous anxiety and trepidation, these feelings quickly gave way to excitement 
and enthusiasm as the prospects of turning the experience into a learning opportunity 
became more apparent. It must be said that this cognitive and emotional switch 
occurred in the context of the first Action Learning Set in January 2012 during which 
peer encouragement and support was facilitated by an expert in a non-coercive 
ambience.  
 
5.6. Summary  
 
This chapter has provided a discussion on the highlights of the change project, 
including the strengths and weaknesses of the project within the context in which it 
was implemented. The chapter has also provided a critical reflection on the author’s 
experience and learning from the process, as well as recommendations on how the 
service could further benefit from the project. Undertaking this project has provided 
the author and the entire change team an invaluable learning experience on the whole 
concept of change and its management. 
“Because things are the way they are, things will not stay the way they are”.  
– Bertolt Brecht 
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Appendix 1: Table showing adverse effects of clozapine 
 Common Uncommon/Unusual Serious/Life 
Threatening 
1. Sedation Colitis Agranulocytosis 
2 Hypersalivation Delirium Thromboembolism 
3 Constipation Eosinophilia Cardiomyopathy 
4 Hypotension Heat stroke Myocarditis  
5 Hypertension Hepatic failure  
6 Tachycardia Ocular pigmentation  
7 Weight gain Pancreatitis  
8 Fever Pericardial effusion  
9 Seizures Pneumonia  
10 Nausea Thrombocytopenia  
11 Nocturnal enuresis Vasculitis  
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Appendix 2: Stakeholders’ Analysis 
 
  
 
 
• HSE Management 
 
 
 
 
 
 
• Hospital Senior Management Team 
• Consultant Psychiatrists 
• Local GPs 
• Clozapine clinic staff 
• Other MDT members  
• Consultant Endocrinologist 
in General Hospital 
 
 
 
• Patients 
• Patient advocacy groups 
 
 
Power 
Interest 
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Appendix 3: SWOT Analysis 
STRENGHTS  
• Good early buy-in 
• Expert and position power of 
change leader (author) 
• External policy environment  
• Internal need to improve 
practice 
• Cost effectiveness of project 
• Strong interest and commitment 
by team 
 
OPPORTUNITIES 
• Parallel development of 
individualised care and treatment 
planning 
• Recently increasing emphasis on 
service-user involvement  
• Ongoing Primary Care Liaison 
project 
• Completion of Masters Degree! 
 
 
WEAKNESSES 
• Prevailing low staff morale in 
HSE and public service 
•  Fear of increased workload by 
nursing staff 
• ‘Role’ culture within the 
organisation 
 
 
 
 
 
THREATS 
• Recruitment embargo - unstable 
staffing levels 
• Precarious relationship with some 
local GPs 
• Change fatigue – ongoing parallel 
changes due to broader service 
reconfiguration agenda 
• Potentially heightened awareness 
of patients to claims and litigations
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Appendix 4: Project Impact Statement 
 How things are done now How things would be following this 
project 
 
Behaviour 
The physical health of patients on 
clozapine is not receiving evidence-
based attention.  
 
Physical examinations and laboratory 
investigations are not systematic 
.  
Abnormal results are not effectively 
followed through.  
 
There is no coordination of care with 
GPs for the management of adverse 
effects. 
The attitude and practice of staff in relation 
to clozapine monitoring will come in line 
with best practice guidelines. 
  
Comprehensive surveillance of relevant 
physical parameters will be carried out on 
an ongoing basis.  
 
Findings will be shared collaboratively 
with patients and their GPs and continuity 
of care between the psychiatry and primary 
will be optimised.  
 
 
Structural 
There are no procedures or 
guidelines with regard to the 
monitoring of patients on clozapine.  
 
There is no protocol for the follow 
up of abnormal laboratory or 
physical examination findings. 
An evidence based proforma will be in 
place to guide clozapine monitoring.  
 
Policies and procedures will be in place for 
the coordination of care between the 
service, the patients and their General 
Practitioners. 
 
 
Personal 
I have long maintained a special 
interest in the interface between 
psychiatry and medical disorders.  
 
I have a particular interest in 
psychopharmacology, and an 
empathic disposition towards the 
adverse effects of medications.  
Through participating in this project, I will 
enhance my knowledge, attitude and 
practice in relation to the physical health of 
the patients under my care.  
 
I will strive to continually improve my 
practice in the area during my career. 
 
 
Cultural 
Attention to the physical health of 
patients on clozapine has at best been 
casual and opportunistic.  
 
Staff  have approached this role with 
only a superficial awareness of the 
ethical and evidence-based 
considerations that underlie such 
practice.  
 
Staff will become accustomed with the 
ethical considerations that underlie the safe 
clinical practices in relation to the adverse 
consequences of prescribed medications.  
 
The structured and systematic approach 
used in introducing the change will help 
embed the revised care process and 
pathway within the cultural fabric of the 
organisation.  
APPENDIX 5: Process maps of old and new care pathways
Flow Chart 1: Old care pathway           Flow Chart 2: New care pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abnormal result 
identified by clozapine 
nurse using new 
protocol 
Patient assessed by 
psychiatrist at 
clozapine clinic to 
determine need for 
intervention 
Letter sent to GP 
using new template 
to request further 
management 
Key‐worker liaises 
with GP to ensure 
care is followed 
through 
GP feedback is 
incorporated into 
patient’s future care 
plan
Abnormal result 
identified incidentally 
Abnormal finding 
filed in clozapine 
clinic chart 
Patient reviewed by 
psychiatrist at next 
OPD with or without 
abnormal test results
Abnormal finding 
possibly addressed 
with or without GP’s 
involvement  
No definite liaison 
with GP regarding 
care plans 
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 Appendix 6: New Proforma for clozapine monitoring 
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Appendix 7: Standardised letter format for communicating abnormal findings to GPs 
 
North Sector
County Mental Health Service
Ireland
Date 
Dr.............................................. 
GP Practice Address 
City Centre 
Ireland 
 
 
Re: Patient Name, DOB 
 Address 
 Diagnosis 
 Current Medications 
 
 
Dear Dr............................... 
 
Routine physical evaluation performed on the above named patient has revealed the 
following abnormalities: 
 
•  ............................................................................................................................. 
• ..............................................................................................................................  
•  .............................................................................................................................. 
•  .............................................................................................................................. 
•  .............................................................................................................................. 
 
Please be advised that these findings may be associated with the antipsychotic medication – 
clozapine. Your urgent attention to this matter would be most appreciated. 
 
Yours sincerely, 
 
Consultant Psychiatrist  
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Appendix 8: Pre and Post Implementation Questionnaire (Staff) 
Dear Colleague,  
Please kindly take a few moments to answer these questions in relation to the routine 
monitoring of patients on clozapine. 
1. How would you rate your knowledge in relation to the adverse effects of clozapine 
treatment? 
a. Poor  
b. Adequate  
c. Very good 
2. How would you rate your own current practice in relation to the monitoring of the 
adverse effects of clozapine treatment? 
a. Poor  
b. Adequate  
c. Very good 
3. How would you rate your attitude in relation to the monitoring of the adverse effects 
of clozapine treatment? 
a. Poor  
b. Adequate  
c. Very good 
4. How would you rate your satisfaction with the current practice of this service in 
relation to the monitoring of patients on clozapine treatment? 
a. Poor  
b. Adequate  
c. Very good 
5. How would you rate your interest in improving the monitoring of patients on 
clozapine treatment within this service? 
a. Poor  
b. Adequate  
c. Very good  
Thank you for taking time to complete this questionnaire.  
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Post-implementation questionnaire (Staff) 
Dear Colleague,  
Please kindly take a few moments to answer these questions in relation to the recent 
change to the monitoring of patients on clozapine. 
1 How would you rate your knowledge in relation to the adverse effects of clozapine 
treatment? 
a. Poor  
b. Adequate 
c. Very good 
2. How would you rate your own current practice in relation to the monitoring of 
adverse effects of clozapine treatment? 
a. Poor  
b. Adequate  
c. Very good 
3. How would you rate your attitude in relation to the monitoring of the adverse effects 
of clozapine treatment? 
a. Poor  
b. Adequate 
c. Very good  
4. How would you rate your satisfaction with the current practice of this service in 
relation to the monitoring of patients on clozapine treatment? 
a. Poor  
b. Adequate  
c. Very good 
5. How would you rate your commitment to continually improving the monitoring of 
patients on clozapine treatment within this service? 
a. Poor  
b. Adequate  
c. Very good 
Thank you for taking time to complete this questionnaire 
Appendix 9: Evaluation Findings 
 
 
 
Fig. 1: Graph showing responses of staff to pre and post change questionnaires. In the survey, 
staff were requested to rate their own knowledge, attitude and Practice in relation to 
monitoring the side effects of clozapine. They were also asked to rate their satisfaction with 
the practice at service level, and their commitment to continued quality improvements.   
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Appendix 10: Project Poster 
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